Communiqués Modalis Therapeutics Corporation

Actions

4883

JP3922600006

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
33,00 ^JPY	0,00%		+6,45%	-41,07%

10/08	Modalis Therapeutics Corporation publie ses résultats pour le semestre clos le 30 juin 2026	CI
12/02	Modalis Therapeutics Corporation publie ses résultats financiers pour l'exercice clos le 31 décembre 2025	CI

Communiqués

25/12	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD	BU
13/05/25	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.	BU
06/01/25	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	BU
28/10/24	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration	AQ
25/10/24	Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).	BU
30/09/24	Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)	BU
07/05/24	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)	BU
15/04/24	Modalis Announces updated strategic plan and business consolidation of US operation	AQ
15/04/24	Modalis Announces Partnership with Ginkgo Bioworks	AQ
12/04/24	Modalis Announces Partnership with Ginkgo Bioworks	BU
13/12/23	Modalis and JCR Pharmaceuticals enter into joint research agreement	BU
19/04/23	Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting	BU
05/07/22	Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)	PU
22/06/22	Modalis Therapeutics : Notice Regarding a Patent Allowance for ‘Method for treating muscular dystrophy by targeting utrophin gene’ in the USA	PU
15/06/22	Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)	PU
20/04/22	Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting	BU
20/04/22	Modalis Therapeutics : to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines at the ASGCT Annual Meeting	PU
15/04/22	Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)	PU
15/04/22	Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)	PU
29/03/22	Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential	PU
29/03/22	Modalis Therapeutics : Announcement of Issuance of Stock Options (Share Acquisition Rights)	PU
22/02/22	Modalis Therapeutics : Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus	PU
07/01/22	Modalis Therapeutics : Announces Termination of Research Collaboration on MDL-204	PU
07/01/22	Modalis Therapeutics : Q＆A regarding Notice of Modalis Announces Termination of a Research Collaboration on MDL-204	PU
15/11/21	Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential	PU